Methods and polynucleotide constructs for treating host cells fo

Details Methods and polynucleotide constructs for treating host cells fo Methods and polynucleotide constructs for treating host cells fo

1992-10-22

1999-01-19

Railey, II, Jonny F.

Chemistry: molecular biology and microbiology

Treatment of micro-organisms or enzymes with electrical or...

Modification of viruses

424 932, 4353201, 514 44, 536 231, 536 232, 536 235, 536 2353, 536 236, 536 237, 536 2372, 536 241, 536 245, C12N 1509, C12N 1511, C12N 1563, C12N 1586

Patent

active

058612904

ABSTRACT:
Host cells may be treated for an infection or a hyperproliferative disorder which is characterized by the presence, in the affected cells, of a trans-acting factor capable of regulating gene expression by inserting into the cells a polynucleotide construct having a cis-acting regulatory sequence which is regulated by the trans-acting factor and an effector gene which renders said cell susceptible to protection or destruction. For example, the cis-acting region may be homologous to the HIV tar region, and the effector gene may encode ricin A or HSV-1 thymidine kinase. Upon infection with HIV, the HIV tat protein activates the tar region, and induces transcription and expression of ricin A, resulting in cell death, or of HSV-1 tk, resulting in cell death upon treatment with dideoxynucleoside agents such as acyclovir and gancyclovir.

REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude et al.
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4650764 (1987-03-01), Temin et al.
patent: 4663281 (1987-05-01), Gillies et al.
patent: 4708818 (1987-11-01), Montanier et al.
patent: 4725669 (1988-02-01), Essex et al.
patent: 4738922 (1988-04-01), Haseltine
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4861719 (1989-08-01), Miller
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5026635 (1991-06-01), Ferguson et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5399346 (1995-03-01), Anderson et al.
Nelson et al., "Gene replacement therapy for inborn errors of purine metabolism," Cold Spring Harbor Symp. Quant. Biol., 51(2): 1065-1071 (1986).
Pizer et al., "A mammalian cell line designed to test the mutagenic activity of anti-herpes nucleosides," Int. J. Cancer, 40: 114-121 (1987).
Maxwell, et al., "Regulated Expression of A Transfected Toxin Gene" Abstract No. N93, J. Cell. Biochem., 0 (10 Part D): 39 (1986).
Maxwell, et al., "HTLV-Regulated Expression of a Transfected Diphtheria Toxin Gene," Abstract No. P314, J. Cell., Biochem., 0 (11 Part D): 67 (1987).
Harrison, et al., "Toward HIV-Regulated Expression of A Diphtheria Toxin A Gene In Transfected Cells," Abstract No. G418, J. Cell. Biochem., 0 (13 Part B): 302 (Jan. 21, 1989).
Aldovini et al., "Humoral and Cell-Mediated Immune Responses to Live Recombinant BCG-HIV Vaccines," Nature, 351:479-482 (1991).
Altmann et al., "Contransfection of ICAM-1 and HLA-DR Reconstitutes Human Antigen-Presenting Cell Function in Mouse L Cells," Nature, 338:512-514 (1989).
Ameisen et al., "Cell Dysfunction and Depletion in AIDS: The Programmed Cell Death Hypothesis," Immunology Today, 12:102-105 (1991).
Anderson et al., "Gene Expression in Implanted Rat Hepatocytes Following Retroviral-Mediated Gene Transfer," Som. Cell and Mol. Genetics, 15:215-227 (1989).
Anderson, W.F., "Prospects for Human Gene Therapy," Science, 226:401-409 (1984).
Armentano et al., "Effect of Internal Viral Sequences on the Utility of Retroviral Vectors," J. Virology, 61:1647-1650 (1987).
Arnold et al., "Vaccine Development for Aids Through Molecular Surgery of a Human Common Cold Virus Surface," J. Cell. Biochem., L401:145 (1990).
Barnd et al., "Specific, Major Histocompatibility Complex-Unrestricted Recognition of Tumor-Associated Mucins By Human Cytotoxic T Cells," Proc. Nat'l Acad. Sci., USA, 86:7159-7163 (1989).
Berkner, K.L., "Development of Adenovirus Vectors for the Expression of Heterologous Genes," BioTechniques, 6:616-629 (1988).
Bernards et al., "Effective Tumor Immunotherapy Directed Against an Oncogene-Encoded Product Using a Vaccinia Virus Vector," Proc. Nat'l Acad. Sci., USA, 84:6854-6858 (1987).
Bernards et al., "N-myc Amplification Causes Down-Modulation of MHC Class I Antigen Expression in Neuroblastoma," Cell, 47:667-674 (1986).
Bix et al., "Rejection of Class I MHC-Deficient Haemopoietic Cells by Irradiated MHC-Matched Mice," Nature, 349:329-331 (1991).
Bolognesi et al., "Prospects of Treatment of Human Retrovirus-Associated Diseases," Cancer Research (Suppl.) 45:4700s-4705s (1985).
Braakman et al., "ICAM-Melanoma Cells Are Relatively Resistant To CD3-Mediated T-Cell Lysis," Int. J. Cancer, 46:475-480 (1990).
Braciale et al., "Antigen Presentation Pathways to Class I and Class II MHC-Restricted T Lymphocytes," Immunology Reviews, 98:95-114 (1987).
Bubenik et al., "Local Administration of Cells Containing an Inserted IL-2 Gene and Producing IL-2 Inhibits Growth to Human Tumors in nu
u Mice," Immunology Letters, 19:279-282 (1988).
Buseyne et al., "Detection of HIV-Specific Cell-mediated Cytotoxicity in the Peripheral Blood from Infected Children," J. Immunology, 150(8):3569-3581 (1993).
Butini et al., "Comparative Analysis of HIV-Specific CTL Activity in Lymphoid Tissue and Peripheral Blood," J. Cell. Biochem. (Suppl.) 18B:147 (Abstract J306) (1994).
Carey, J., "Human Gene Therapy: After a Lot of Looking, Now the Leap," Business Week, Science & Technology, pp. 133 & 136 (May 1, 1989).
Carmichael et al., "Quantitative Analysis of the Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytotoxic T Lymphocyte (CTL) Response at Different Stages of HIV-1 Infection: Differential CTL Responses to HIV-1 and Epstein-Barr Virus in Late Disease," J. Exp. Med., 177:249-256 (1993).
Carr et al., "Genetic Transformation of Murine Bone Marrow Cells to Methotrexate Resistance," Blood, 62(1):180-185 (1983).
Cepko, C., "Retrovirus Vectors and Their Applications in Neurobiology," Neuron, 1:345-353 (1988).
Chada et al., "Cross-Reactive Lysis of Human Targets Infected with Prototypic and Clinical Human Immunodeficiency Virus Type 1 (HIV-1) Strains by Murine Anti-HIV-1 IIIB env-Specific Cytotoxic T Lymphocytes," J. Virol., 67(6):3409-3417 (1993).
Chakrabarti et al., "Expression of the HTLV-III Envelope Gene by a Recombinant Vaccinia Virus," Nature, 320:535-537 (1986).
Chan et al., "Mammalian Saccoma-Leukemia Viruses. I. Infection of Feline, Bovine, and Human Cell Cultures With Snyder-Theilen Feline Sarcoma Virus," J. Nat'l Cancer Inst., 52(2):473-481 (1974).
Cline et al., "Gene Transfer in Intact Animals," Nature, 284:422-425 (1980).
Collins et al., "Transfer of Functional EGF Receptors to an IL3-Dependent Cell Line," J. Cell. Physiology, 137:292-298 (1988).
Cone et al., "High-Efficiency Gene Transfer Into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus with Broad Mammalian Host Range," Proc. Nat'l Acad. Sci. USA, 81:6349-6353 (1984).
Cone et al., "HLA-DR Gene Expression in a Proliferating Human Thyroid Cell Clone (12S)" Endocrinology, 123(4):2067-2074 (1988).
Cortes et al., "Successful Immunotherapy in a Murine Metastasizing Fibrosarcoma Model," J. Surg. Onco., 25:289-295 (1984).
Crowley et al., "Generation of Human Antologous Melanoma-specific Cytotoxic T-Cells Using HLA-A2-matched Allogeneic Melanomas," Cancer Research, 50:492-498 (1990).
Culliton, B.J., "Designing Cells to Deliver Drugs," Science(News & Comment), 246:746-751 (1989).
Dadaglio et al., "Enhancement of HIV-specific Cytotoxic T Lymphocytes Responses by Zidovudine (AZT) Treatment," Clin. Ex. Immunol., 87:7-14 (1992).
Dallo et al., "Humoral Immune Response Elicited by Highly Attenuated Variants of Vaccinia Virus and by an Attenuated Recombinant Expressing HIV-1 Envelope Protein," Virology, 173:323-329 (1989).
De Baetselier et al., "Differential Expression of H-2 Gene Products in Tumour Cells is Associated with Their Metastatogenic Properties," Nature, 288:179-181 (Nov. 13, 1980).
Deen et al., "A Soluble Form of CD4 (T4) Protein Inhibits AIDS Virus Infection," Nature, 331:82-84 (Jan. 7, 1988).
Doherty et al., "Recombinant Vaccinia Viruses and The Development of Immunization Strategies Using Influenza Virus," J. Inf. Diseases, 159(6):1119-1122 (Jun., 1989).
Donner et al.,, "McDonough Feline Sarcoma Virus: Characterization of the Molecularly Cloned Provirus and Its Feline Oncogene (v-fms)," J. Virol, 41(2):489-500 (1982).
Earl et al., "Biological and Immunological Properties of Human Immunodeficiency Virus Type 1 Envelo

Affiliated with

Also associated with

Rating

Methods and polynucleotide constructs for treating host cells fo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and polynucleotide constructs for treating host cells fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and polynucleotide constructs for treating host cells fo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1246033